A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 152
- 试验地点
- 1
- 主要终点
- Percentage of subjects with COVID-19 disease progression
研究概览
简要总结
The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.
详细描述
This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30 days. It is proposed that Quercetin Phytosome will contribute to boosting the natural immunity of the subjects and will help in preventing the COVID-19 disease progression i.e preventing the need of hospitalisation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of either gender
- •Confirmed SARS-CoV-2 infection by RT-PCR
- •Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in self-isolation within 3 days of SARS-CoV-2 infection.
- •Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous cough, a loss or change to sense of smell or taste
- •Patients who have signed informed consent.
排除标准
- •Patients with proven hypersensitivity or allergic reaction to quercetin
- •Manifest contrary will
研究组 & 干预措施
Standard of care
This arm will receive the standard COVID-19 care as per the hospital physician guidelines.
干预措施: Standard COVID-19 care (Drug)
Quercetin Phytosome
This arm will receive standard COVID-19 care + Quercetin Phytosome
干预措施: Standard COVID-19 care (Drug)
Quercetin Phytosome
This arm will receive standard COVID-19 care + Quercetin Phytosome
干预措施: Quercetin Phytosome (Dietary Supplement)
结局指标
主要结局
Percentage of subjects with COVID-19 disease progression
时间窗: From day 1 to day 30
Percentage of subjects who require hospitalisation
次要结局
未报告次要终点
研究者
Prof. Dr. Ikram Din Ujjan, MBBS, PhD
Principal Investigator
Liaquat University of Medical & Health Sciences